Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 6;11:740. doi: 10.1038/s41467-020-14604-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Schematic depicting the use of dCas9-KRAB-based CRISRPi to target MYC-associated PVT1 or BENC enhancers. b ChIP-qPCR analysis of H3K27ac enrichment in K562 cells transduced with a scrambled sgRNA or sgRNA targeted to the PVT1 and BENC loci. Data were shown as mean ± S.D; n = 4 from four independent assays, **P = 0.01 (E1), 0.0007 (E2), 0.0006 (E3), 0.0001 (E4), and 0.01 (PVT1), by two-tailed Student’s t test. c–e Transcription (c), protein (d) levels and cell viability (e) of K562 cells expressing dCas9-KRAB and two independent sgRNAs targeted to PVT1 after BETi treatment. K562 cells transduced with dCas9-KRAB and scrambled sgRNAs were used as control. Data were shown as mean ± S.D; n = 3 from three independent assays, **P = 0.0002 (c) and 0.0004 (e), by two-tailed Student’s t test. f Schematics depicting the use of the dCas9-p300^Core-based CRISRPa system to target MYC-associated PVT1 enhancers. g ChIP-qPCR analysis of H3K27ac enrichment in THP1, MOLM-13 and murine MLL-AF9 parental cells transduced with a scrambled sgRNA or sgRNA targeted to the PVT1 locus. Data were shown as mean ± S.D; n = 3 from three independent assays, **P = 0.028 (AF9), 0.012 (MOLM-13) and 0.011 (THP1) by two-tailed Student’s t test. h–j Comparison of gene transcription (h), protein expression (i) levels and dose response curves (j) of THP1 cells expressing dCas9-p300^Core and two independent sgRNAs targeted to PVT1 after BETi treatment. THP1 cells transduced with dCas9-p300^Core and scrambled sgRNAs were used as control. Data were shown as mean ± S.D; n = 3 from three independent assays, **P = 0.0001 (sg-scram) and 0.0005 (sg-PVT1), by two-tailed Student’s t test.